SSAA09E2
产品说明书
 |
同义名 : | - |
| CAS号 : | 883944-52-3 | |
| 货号 : | A1481140 | |
| 分子式 : | C16H20N4O2 | |
| 纯度 : | 98%+ | |
| 分子量 : | 300.36 | |
| MDL号 : | N/A | |
| 存储条件： |
Pure form Inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Human Coronaviruses (HCoV), periodically emerging across the world, are potential threat to humans such as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) - diseases termed as COVID-19[2].The SARS-CoV-2 mechanism of infection process is triggered by direct binding of the SARS-CoV-2 receptor-binding domain (RBD) to the host cell receptor, Angiotensin-converting enzyme 2 (ACE2). Both Nilotinib and SSAA09E2 can induce significant conformational changes in the ACE2-RBD complex, intervene with the hydrogen bonds, and influence the flexibility of proteins. Moreover, essential dynamics analysis suggests that the presence of small molecules can trigger large-scale conformational changes that may destabilize the ACE2-RBD complex[3].SSAA09E2 is an inhibitor of SARS-CoV replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, angiotensin converting enzyme 2 (ACE2). SSAA09E2 inhibit fusion only when added prior to overlay of SARS-S 293T cells with ACE2-expressing TZM-bl cells,consistent with the above data suggesting that it interferes directly with SARS-S RBD–ACE2 interactions.[4]. Experiment showed that SSAA09E2 can induce significant conformational changes in the ACE2-RBD complex, intervene with the hydrogen bonds, and influence the flexibility of proteins[3]. SSAA09E2 with remdesivir or favipiravir could also significantly restrain the COVID-19 virus at the entry and replication stage[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.33mL 0.67mL 0.33mL |
16.65mL 3.33mL 1.66mL |
33.29mL 6.66mL 3.33mL |
| 参考文献 |
|---|